NCI Community Oncology Research Program - Kansas City (NCORP-KC)
NCI Community Oncology Research Program - Kansas City (NCORP-KC)




Lung Clinical Trials

Cancer clinical trials are research studies for developing better ways of detecting, treating, and eventually preventing cancer. By taking part in a clinical trial, you are among the first to receive new research treatments before they are widely available. Your participation in a clinical trial will influence the future direction of cancer care.

 

If you are interested in participating in a clinical trial, consult with your physician. Please note: clinical trials are not risk free. Patients must explore the options that are best for their individuals needs with the help of their physician.



Non-Small Cell - Stage I

Alliance A081105 - "Randomized Double Blind Placebo Controlled Study of Erlotinib or Placebo in Patients with Completely Resected Epidermal Growth Factor Receptor (EGFR) Mutant Non-small Cell Lung Cancer (NSCLC)"

CANCER TYPE: Non-Small Cell - Stage I
RESEARCH BASE: Alliance A081105
NCT NUMBER: 02193282
Protocol Summary: VIEW SUMMARY
Consent Form: VIEW CONSENT FORM
BRIEF DESCRIPTION

NSC, Stg IB (>4cm), II, or IIIA, non-squamous, completely resected, prior regist to A151216 (ALCHEMIST); Erlotinib vs placebo






Alliance A151216 - "Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial (ALCHEMIST)"

CANCER TYPE: Non-Small Cell - Stage I
RESEARCH BASE: Alliance A151216
NCT NUMBER: 02194738
Protocol Summary: VIEW SUMMARY
Consent Form: VIEW CONSENT FORM
BRIEF DESCRIPTION

NSC, Stg IB, II, or IIIA, resectable, no neo-adjuv chemo or RT; Study of Enrichment Marker Identification & Sequencing (EGFR & ALK genotyping)






CTSU E4512 - "A Phase III Double-Blind Trial for Surgically Resected Early Stage Non-Small Cell Lung Cancer: Crizotinib Versus Placebo for Patients with Tumors Harboring the Anaplastic Lymphoma Kinase (ALK) Fusion Protein"

CANCER TYPE: Non-Small Cell - Stage I
RESEARCH BASE: CTSU E4512
NCT NUMBER: 02201992
Protocol Summary: VIEW SUMMARY
Consent Form: VIEW CONSENT FORM
BRIEF DESCRIPTION

NSC, Stg IB (>4cm), II, or IIIA, non-squamous, completely resected, prior regist to A151216 (ALCHEMIST); Crizotinib vs placebo






ECOG-ACRIN EA5142 - "Adjuvant Nivolumab in Resected Lung Cancers (ANVIL) A Randomized Phase III Study of Nivolumab After Surgical Resection and Adjuvant Chemotherapy in Non-Small Cell Lung Cancers"

CANCER TYPE: Non-Small Cell - Stage I
RESEARCH BASE: ECOG-ACRIN
NCT NUMBER: NCT02595944
Protocol Summary: VIEW SUMMARY
Consent Form: VIEW CONSENT FORM
BRIEF DESCRIPTION

NSC completely resected, IB, II, IIIA, EGFR and ALK wild-type, prior registration to A151216 (ALCHEMIST), nivolumab vs observation






Non-Small Cell - Stage II

Alliance A081105 - "Randomized Double Blind Placebo Controlled Study of Erlotinib or Placebo in Patients with Completely Resected Epidermal Growth Factor Receptor (EGFR) Mutant Non-small Cell Lung Cancer (NSCLC)"

CANCER TYPE: Non-Small Cell - Stage II
RESEARCH BASE: Alliance A081105
NCT NUMBER: 02193282
Protocol Summary: VIEW SUMMARY
Consent Form: VIEW CONSENT FORM
BRIEF DESCRIPTION

NSC, Stg IB (>4cm), II, or IIIA, non-squamous, completely resected, prior regist to A151216 (ALCHEMIST); Erlotinib vs placebo






Alliance A151216 - "Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial (ALCHEMIST)"

CANCER TYPE: Non-Small Cell - Stage II
RESEARCH BASE: Alliance A151216
NCT NUMBER: 02194738
Protocol Summary: VIEW SUMMARY
Consent Form: VIEW CONSENT FORM
BRIEF DESCRIPTION

NSC, Stg IB, II, or IIIA, resectable, no neo-adjuv chemo or RT; Study of Enrichment Marker Identification & Sequencing (EGFR & ALK genotyping)






CTSU E4512 - "A Phase III Double-Blind Trial for Surgically Resected Early Stage Non-Small Cell Lung Cancer: Crizotinib Versus Placebo for Patients with Tumors Harboring the Anaplastic Lymphoma Kinase (ALK) Fusion Protein"

CANCER TYPE: Non-Small Cell - Stage II
RESEARCH BASE: CTSU E4512
NCT NUMBER: 02201992
Protocol Summary: VIEW SUMMARY
Consent Form: VIEW CONSENT FORM
BRIEF DESCRIPTION

NSC, Stg IB (>4cm), II, or IIIA, non-squamous, completely resected, prior regist to A151216 (ALCHEMIST); Crizotinib vs placebo






ECOG-ACRIN EA5142 - "Adjuvant Nivolumab in Resected Lung Cancers (ANVIL) A Randomized Phase III Study of Nivolumab After Surgical Resection and Adjuvant Chemotherapy in Non-Small Cell Lung Cancers"

CANCER TYPE: Non-Small Cell - Stage II
RESEARCH BASE: ECOG-ACRIN
NCT NUMBER: NCT02595944
Protocol Summary: VIEW SUMMARY
Consent Form: VIEW CONSENT FORM
BRIEF DESCRIPTION

NSC completely resected, IB, II, IIIA, EGFR and ALK wild-type, prior registration to A151216 (ALCHEMIST), nivolumab vs observation






Non-Small Cell - Stage IIIA

Alliance A081105 - "Randomized Double Blind Placebo Controlled Study of Erlotinib or Placebo in Patients with Completely Resected Epidermal Growth Factor Receptor (EGFR) Mutant Non-small Cell Lung Cancer (NSCLC)"

CANCER TYPE: Non-Small Cell - Stage IIIA
RESEARCH BASE: Alliance A081105
NCT NUMBER: 02193282
Protocol Summary: VIEW SUMMARY
Consent Form: VIEW CONSENT FORM
BRIEF DESCRIPTION

NSC, Stg IB (>4cm), II, or IIIA, non-squamous, completely resected, prior regist to A151216 (ALCHEMIST); Erlotinib vs placebo






Alliance A151216 - "Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial (ALCHEMIST)"

CANCER TYPE: Non-Small Cell - Stage IIIA
RESEARCH BASE: Alliance A151216
NCT NUMBER: 02194738
Protocol Summary: VIEW SUMMARY
Consent Form: VIEW CONSENT FORM
BRIEF DESCRIPTION

NSC, Stg IB, II, or IIIA, resectable, no neo-adjuv chemo or RT; Study of Enrichment Marker Identification & Sequencing (EGFR & ALK genotyping)






CTSU E4512 - "A Phase III Double-Blind Trial for Surgically Resected Early Stage Non-Small Cell Lung Cancer: Crizotinib Versus Placebo for Patients with Tumors Harboring the Anaplastic Lymphoma Kinase (ALK) Fusion Protein"

CANCER TYPE: Non-Small Cell - Stage IIIA
RESEARCH BASE: CTSU E4512
NCT NUMBER: 02201992
Protocol Summary: VIEW SUMMARY
Consent Form: VIEW CONSENT FORM
BRIEF DESCRIPTION

NSC, Stg IB (>4cm), II, or IIIA, non-squamous, completely resected, prior regist to A151216 (ALCHEMIST); Crizotinib vs placebo






ECOG-ACRIN EA5142 - "Adjuvant Nivolumab in Resected Lung Cancers (ANVIL) A Randomized Phase III Study of Nivolumab After Surgical Resection and Adjuvant Chemotherapy in Non-Small Cell Lung Cancers"

CANCER TYPE: Non-Small Cell - Stage IIIA
RESEARCH BASE: ECOG-ACRIN
NCT NUMBER: NCT02595944
Protocol Summary: VIEW SUMMARY
Consent Form: VIEW CONSENT FORM
BRIEF DESCRIPTION

NSC completely resected, IB, II, IIIA, EGFR and ALK wild-type, prior registration to A151216 (ALCHEMIST), nivolumab vs observation






RTOG 1306 - "A RANDOMIZED PHASE II STUDY OF INDIVIDUALIZED COMBINED MODALITY THERAPY FOR STAGE III NON-SMALL CELL LUNG CANCER (NSCLC)"

CANCER TYPE: Non-Small Cell - Stage IIIA
RESEARCH BASE: NRG
NCT NUMBER: NCT01822496
Protocol Summary: VIEW SUMMARY
Consent Form: VIEW CONSENT FORM
BRIEF DESCRIPTION

NSCLC, unresectable IIIA or IIIB, EGFR TK or ALK Tran L, chemo radiation w/wo Erlotinib or Crizotinib






Non-Small Cell - Stage IV

SWOG S1400 - "A Biomarker-Driven Master Protocol for Previously Treated Squamous Cell Lung Cancer"(Lung-Map)

CANCER TYPE: Non-Small Cell - Stage IV
RESEARCH BASE: SWOG S1400
NCT NUMBER: NCT02154490
Protocol Summary: VIEW SUMMARY
Consent Form: VIEW CONSENT FORM
Additional Consent Form: VIEW CONSENT FORM 2
BRIEF DESCRIPTION

Squamous cell lung ca, Stg IV or recurrent, 1 prior front-line platinum-based chemo regimen w/disease progression; CLIA Biomarker Profiling ---> sub-study assignments based on results. Mandatory tissue submission & Central Review of scans.






SWOG S1400G - "A Phase II Study of Talazoparib (BMN 673) in Patients with Homologous Recombination Repair Deficiency Positive Stage IV Squamous Cell Lung Cancer (Lung-Map Sub-Study)"

CANCER TYPE: Non-Small Cell - Stage IV
RESEARCH BASE: SWOG
NCT NUMBER: NCT02154490
Protocol Summary: VIEW SUMMARY
Consent Form: VIEW CONSENT FORM
BRIEF DESCRIPTION

Squamous cell lung ca, Stage IV, Talazoparib






SWOG S1400I - "A PHASE III RANDOMIZED STUDY OF NIVOLUMAB PLUS IPILIMUMAB VERSUS NIVOLUMAB FOR PREVIOUSLY TREATED PATIENTS WITH STAGE IV SQUAMOUS CELL LUNG CANCER AND NO MATCHING BIOMARKER (LUNG-MAP SUB-STUDY)"

CANCER TYPE: Non-Small Cell - Stage IV
RESEARCH BASE: SWOG
NCT NUMBER: NCT02785952
Protocol Summary: VIEW SUMMARY
Consent Form: VIEW CONSENT FORM
BRIEF DESCRIPTION

Squamous cell lung ca, Stage IV, no matching biomarker, Nivolumab vs. Nivolumab plus Ipilimumab






SWOG S1403 - "A Randomized Phase II/III Trial of Afatinib Plus Cetuximab Versus Afatinib Alone in Treatment-Naive Patients with Advanced, EGFR Mutation Positive Non-Small Cell Lung Cancer (NSCLC) (BI 1200.124)."

CANCER TYPE: Non-Small Cell - Stage IV
RESEARCH BASE: SWOG
NCT NUMBER: NCT02438722
Protocol Summary: VIEW SUMMARY
Consent Form: VIEW CONSENT FORM
BRIEF DESCRIPTION

NSC, Stg IV or recurrent, EGFR exon 19 deletion or exon 21 (L858R) substitution mutation, Afatinib + Cetuximab vs Afatinib alone.









  © 2013-2017 All Rights Reserved. Privacy Policy | Terms & Conditions
NCI Community Oncology Research Program - Kansas City (NCORP-KC)
Questions? Call: +1-913-948-5588 | Contact Us
4121 W. 83rd St., Suite 259 Prairie Village, KS 66208 USA